Empro Group Inc. Ordinary shares (EMPG)vsJohnson & Johnson (JNJ)
EMPG
Empro Group Inc. Ordinary shares
$17.36
0.00%
HEALTHCARE · Cap: $143.05M
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 1756824% more annual revenue ($96.36B vs $5.48M). JNJ leads profitability with a 21.8% profit margin vs 13.7%. JNJ trades at a lower P/E of 26.3x. JNJ earns a higher WallStSmart Score of 59/100 (C).
EMPG
Hold47
out of 100
Grade: D+
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EMPG.
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 66 in profit
Strong operational efficiency at 36.1%
Revenue surging 141.6% year-over-year
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
Trading at 17.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : EMPG
The strongest argument for EMPG centers on Return on Equity, Operating Margin, Revenue Growth. Revenue growth of 141.6% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : EMPG
The primary concerns for EMPG are Price/Book, EPS Growth, Market Cap. A P/E of 192.9x leaves little room for execution misses.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
EMPG profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.
EMPG is growing revenue faster at 141.6% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (59/100 vs 47/100), backed by strong 21.8% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Empro Group Inc. Ordinary shares
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Empro Group Inc., through its subsidiary, sells healthcare and beauty products in Malaysia and internationally. The company is headquartered in Shah Alam, Malaysia.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?